Login to Your Account


PDUFA DATA SURPRISE FOR I.V. BID

Amgen Inc.'s bid to get approved an I.V. replacement for its oral Sensipar hit choppy seas in the form of a complete response letter from the FDA on its PDUFA date.

more »


Opinion


Partners in Focus